# OnCo record paper-napoli-1-nanoliposomal-irinotecan-lancet-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-napoli-1-nanoliposomal-irinotecan-lancet-2016" ;
  schema:name "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial"@en ;
  schema:description "The 2016 trial that gave patients whose pancreatic cancer had grown through gemcitabine a proven second treatment: liposomal irinotecan with fluorouracil lengthened survival from about four to six months."@en ;
  schema:url <https://onco.cc/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)00986-1>, <https://pubmed.ncbi.nlm.nih.gov/26615328/>, <https://clinicaltrials.gov/study/NCT01494506> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(15)00986-1> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Wang-Gillam A, Li CP, Bodoky G, et al." ;
  onco:related <https://onco.cc/key-papers/paper-napoli-3-lancet-2023/>, <https://onco.cc/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/nalirifox/> ;
  onco:companies <https://onco.cc/companies/ipsen/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:trials <https://onco.cc/trials/napoli-3/> ;
  onco:people <https://onco.cc/people/daniel-von-hoff/> ;
  onco:journals <https://onco.cc/journals/lancet/> .